Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05555862
Other study ID # ART-AIN IIB
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date February 10, 2023
Est. completion date December 31, 2024

Study information

Verified date May 2024
Source Frantz Viral Therapeutics, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)


Description:

Eligible participants in this study are randomized 2:1 to receive either artesunate or placebo suppositories for the treatment of anal HSIL. Both groups receive four 5-day cycles of suppositories, at weeks 0, 2, 4, and 6. At least two of the dosing visits are done in person. The remaining dosing visits may be done as telehealth visits (suppositories are mailed to the patient's home). Participants are followed closely with anoscopy or high resolution anoscopy (HRA) at weeks 8, 18, 30, and 42. After the week 18 HRA visit, participants who have at least partial response will be followed with HRA at week 30. Participants who are found to be non-responders at week 18 will undergo standard of care ablation. Participants who are found to have anal HSIL at weeks 30 or 42 will be followed according to standard of care procedures. Primary Objective: To evaluate the complete and partial histopathologic response to four 5-day cycles of artesunate suppositories in adult patients with biopsy-proven HPV-associated intra-anal HSIL (18 weeks). Secondary Objectives: Efficacy: - To evaluate the viral clearance after four 5-day cycles of artesunate suppositories in adults with biopsy-proven HPV-associated intra-anal anal HSIL over the study window (42 weeks) - To evaluate complete and partial intra-anal histopathologic response after the week 18 time point but over the study window (30 weeks). - To evaluate complete and partial peri-anal histopathologic response following artesunate suppositories over the course of the study (42 weeks). - To evaluate persistence of response throughout the study window (42 weeks) Safety: To evaluate the safety of artesunate suppositories for the treatment of intra-anal HSIL.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 17
Est. completion date December 31, 2024
Est. primary completion date December 28, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult men and women age = 18 years - Capable of informed consent - Biopsy-confirmed intra-anal high-grade dysplasia (AIN 2, AIN 3, anal HSIL) by HRA. Patients must have residual anal HSIL lesions after diagnostic biopsies, as documented by HRA. This includes patients who are newly diagnosed with anal HSIL as well as those who have recurrent anal HSIL after medical therapy or surgical therapy. Patients who have intra-anal HSIL and also have peri-anal HSIL may be enrolled in the study. - Women of childbearing potential agree to use birth control for the duration of the study. - Laboratory values at Screening of: 1. Serum alanine transaminase (SGPT/ALT) < 5 x upper limit of normal (ULN) 2. Serum aspartate transaminase (SGOT/AST) < 5 x ULN 3. Serum Bilirubin (total) < 2.5 x ULN 4. Serum Creatinine = 1.5 x ULN - Electrocardiogram (ECG) with no clinically significant findings as assessed by the Investigator. - Weight = 50kg Exclusion Criteria: - Pregnant and nursing women - Diagnosis of low-grade anal dysplasia (AIN 1, LSIL), without the concomitant diagnosis of anal HSIL, by HRA - Concurrent anal, vulvar, cervical, or penile cancer - HIV seropositivity - Currently receiving systemic chemotherapy or radiation therapy for another cancer. - Patients who are on medical treatment with systemic immunosuppressants or steroids (e.g., active autoimmune disease) - Concomitant use of strong Uridine glucuronyl transferases (UGT) inhibitors - Concomitant use of imiquimod or 5-fluorouracil (5-FU) for the duration of the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Artesunate
artesunate formulated as intra-anal suppositories
Placebo
placebo intra-anal suppository

Locations

Country Name City State
United States Anal Dysplasia Clinic MidWest Chicago Illinois
United States Laser Surgery Care New York New York
United States Anal Neoplasia and Cancer Research and Education Center San Francisco California

Sponsors (5)

Lead Sponsor Collaborator
Frantz Viral Therapeutics, LLC Amarex CRO, Anal Dysplasia Clinic MidWest, Laser Surgery Care, University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of participants with Treatment-Emergent Adverse Events (TEAE) Number of participants who had adverse events, as defined by CTCAE v5.0, related to the study intervention 12 weeks
Other Number of participants who withdrew from the study due to TEAEs Number of participants who were withdrawn from the study due to adverse events related to the study drug 12 weeks
Other Changes in vital signs over the study window Number of participants who had clinically significant changes in vital signs 42 weeks
Other Changes in physical examination abnormalities Number of participants who had clinically significant changes in physical examination abnormalities 42 weeks
Other Clinically significant changes in ECG between baseline and post dosing Number of participants who had clinical significant changes in ECG between pre-dosing and post dosing 8 weeks
Primary Number of subjects with complete and partial response by week 18 Number of participants who achieve complete or partial response after 4 5-day cycles of artesunate as determined by HRA-directed biopsy(ies) 18 weeks
Secondary Number of participants who have achieved clearance of detectable human papilloma virus (HPV) over the study window Number of participants who had HPV strains detected at study entry which become undetectable within the study window 42 weeks
Secondary Number of participants with complete and partial response after week 18 but over the study window Number of participants who achieve complete or partial response after week 18, as documented by HRA-directed biopsy(ies) 30 weeks
Secondary Number of participants who achieve complete and partial response of peri-anal HSIL, following 4 cycles of intra-anal artesunate suppositories, as determined by HRA-directed biopsy Number of participants who had both peri-anal and intra-anal HSIL, whose peri-anal HSIL achieves complete or partial response following 4 cycles of intra-anal artesunate suppositories 42 weeks
Secondary Number of participants who undergo complete response who maintain their response over the study window Number of participants who complete or partial response who maintain this response over the study window 42 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04098744 - Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) Phase 2
Completed NCT04083196 - A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years Phase 1
Completed NCT04191967 - Thermocoagulation for Treatment of Precancerous Cervical Lesions N/A
Withdrawn NCT04430907 - HPV Vaccine in Postpartum Women
Recruiting NCT02593968 - Yallaferon in Chinese Population Phase 2
Completed NCT04711265 - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Completed NCT02263378 - A New Supplement for the Immune Response to HPV Infection N/A
Completed NCT05234112 - Prevention and Screening Towards Elimination of Cervical Cancer N/A
Completed NCT04590521 - HPV Vaccine Immunity in High-risk Women Phase 4
Recruiting NCT05829629 - Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women Phase 1
Recruiting NCT06052033 - Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection N/A
Recruiting NCT05051852 - HPV Viral Load in Predicting the Prognosis of LSIL
Completed NCT04155294 - Re-Evaluation of Annual Cytology Using HPV Testing to Upgrade Prevention in Women Living With HIV
Active, not recruiting NCT06452004 - Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC) N/A
Completed NCT06177236 - Clinic or Self-Sampling for Cervical Cancer Screening N/A
Active, not recruiting NCT04794660 - The Study for the "Cervical Cancer Screening and Treatment Algorithms Study Using HPV Testing in Africa" Phase 3
Recruiting NCT05509413 - DEFLAGYN® Vaginal Gel and Spontaneous Remission and Regression of Unclear Cervical Smears and HPV High-risk Infections N/A
Recruiting NCT06137950 - Interferon Alpha Therapy for Cervical CINI and HPV Infection Phase 1
Recruiting NCT04171505 - Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN.
Active, not recruiting NCT05524025 - The SPOT-HPV Study